Rational pharmacotherapy for Alzheimer's disease

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease is commonly encountered by physicians in all specialties. The anticholinesterase inhibitors tacrine and donepezil are FDA-approved to treat the disease, and many more agents are being studied. Such agents may reverse the underlying disease process, salvage injured neurons, prevent amplification of neuronal death, or replace neurotransmitter loss after cell death occurs. This article presents a rational framework for understanding at which step in the neurodegenerative sequence various agents act. A discussion of the noncognitive symptoms of Alzheimer's disease and available treatment options for these ensues, followed by the presentation of a framework for providing comprehensive care consisting of treatment of the disease and its symptoms, as well support for the patient and family/caregiver.

Original languageEnglish (US)
Pages (from-to)5-10
Number of pages6
JournalMedical Update for Psychiatrists
Volume2
Issue number1
DOIs
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Rational pharmacotherapy for Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this